| We describe the discovery and identification of an endogenous Aβ anti-oligomer substance, 3-sulfopropanoic acid (3-SPA), in the human brain. |
| 3-SPA is the primary metabolite of ALZ-801, a prodrug of tramiprosate that is in clinical development for the treatment of Alzheimer’s disease. |
| 3-SPA penetrates the brain and, in a tramiprosate phase III North American (NA) trial, achieved brain concentrations associated with prevention of Aβ42 oligomer formation and clinical outcome benefit in patients with Alzheimer’s disease carrying the ε4 allele of the apolipoprotein E gene. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.